Incidence Rate of Heart Failure After Acute Myocardial Infarction With Optimal Treatment

Harbin Medical University

Status: Completed

Conditions: Heart Failure; Acute Myocardial Infarction

Study type: Observational

Funder types: Other

Identifiers

NCT03297164

2016YFC1301101

Details and patient eligibility

About

The main purpose of this study is to build a multi-center, prospective and regionally representative acute myocardial infarction(AMI) cohort，and build a study platform for heart failure caused by AMI; To explore the 1 year incidence rate of heart failure after AMI given the optimized treatment and the treatment model affecting the incidence rate of heart failure, and finally to reduce the incidence rate of heart failure by 5%.

Full description

the study aim to enroll 12000 acute myocardial infartion (AMI) patients, including ST-segment elevation myocardial infarction (STEMI) and non ST-segment elevation myocardial infarction (NSETMI), Patients were divided into two groups(optimized group and un-optimized group) according to treatment models they accepted in 20 reginally representative hosptials of China. whether optimizaed or not is judged by 4 four aspects,including emergency treatment procedure, pre-infusion medication, reperfusion strategy selection, and early rehabilitation after reperfusion.Patients were followed at 1 month, 6 months and 12 months. The physical condition and clinical events(heart failure, death, re-infarction, revascularization, apoplexy, malignant arrhythmias, bleeding events, other adverse events)were collected at follow up.

Enrollment: 12,043 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• age≥18 years
• diagnosed acute myocardial infarction
• signed the informed consent form

Exclusion criteria

• AMI is caused by surgery, trauma, gastrointestinal bleeding or complications of PCI;
• AMI occurred in patients who have been hospitalized for other reasons;
• patients with previous history of chronic heart failure;
• researchers judging that patient's compliance was poor and could not complete the study according to the requirements.
• life expectancy is less than 12 months;
• heart transplant patients;
• patients with tumors;

Trial design

12,043 participants in 2 patient groups

optimized group

Description:

the patients in this group have been given the suggestive treatment from guideline.

un-optimized group

Description:

the patients in this group have not been given the suggestive treatment from guideline.